CCL18 and idiopathic interstitial pneumonia: In post hoc assessment of that trial, CCL18 in blood, and not other baseline biomarkers such as CCL13 and CXCL13, was the most consistent predictor of disease progression across IPF cohorts, suggesting its potential to inform new target discovery and clinical trial design [84].